Uterine Artery Embolization for Symptomatic Leiomyomata
Uterine Artery Embolization for Symptomatic Leiomyomata
复制标题
DOI：
10.1007/s00270-014-1031-x
复制
发表时间：
2015-06-01
影响因子：
2.9
通讯作者：
Reekers, Jim A.
中科院分区：
文献类型：
--
作者：
van Overhagen, Hans;Reekers, Jim A.
经导管子宫动脉栓塞（UAE）治疗肌瘤是Ravina于1995年首次报道的。血管介入放射学领域的不断进步促进了阿联酋的发展，通过发展低姿态导管和颗粒栓塞，如聚乙烯醇颗粒（PVA）、PVA微球和三丙烯酸基明胶微球（TAGM）。前瞻性随机研究，如EMMY和REST试验，将UAE与子宫切除术进行比较，科学地证明了UAE在治疗有症状的女性肌瘤中占有一席之地[2,3]。子宫切除或栓塞后5年的生活质量相等。一些登记和非随机试验支持了这些发现。试验表明，对于有症状的肌瘤引起月经过多的妇女，UAE应该作为子宫切除术的替代方案（1级）。本文件提供了有关阿联酋治疗症状性子宫肌瘤的质量保证指南。
Transcatheter uterine artery embolization (UAE) for treatment of fibroids was first reported by Ravina in 1995 [1]. The continuous advance in the field of vascular Interventional Radiology has facilitated UAE, through the development of low profile catheters and particulate emboli such as polyvinyl alcohol particles (PVA), PVA microspheres and trisacryl gelatine microspheres (TAGM). Prospective randomized studies such as the EMMY and REST trial that compare UAE with hysterectomy have proven scientifically that there is a place for UAE in the treatment of women with symptomatic fibroids [2, 3]. The QOL 5 years after hysterectomy or embolization is equal. Several registries and non-randomized trials have supported these findings. The trials have shown that UAE should be offered to women with symptomatic fibroids causing menorrhagia, as an alternative to hysterectomy (Level 1). The present document provides quality assurance guidelines regarding UAE for the treatment of symptomatic uterine fibroids.